CD8A and non-small cell lung carcinoma: Recent studies have demonstrated that therapeutic depletion of the CCR8+Treg subset combined with αPD-1 can efficiently activate dendritic cells and enhance CD8+T cells cytotoxicity, yielding pronounced antitumor effects in various NSCLC mouse models (127).